From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.It will mean all newborn ...

A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

Sanofi joins force with Samitivej International Children’s Hospital to launch the “Together Against RSV” awareness campaign in Thailand, with the support from the Pediatric Infectious Disease Society ...

Getting vaccinated during pregnancy protects your newborn from severe infection during the first critical months of life.

Estimated effectiveness was 65% against hospitalization, 74% against pediatric intensive care unit admission, and 64% against ...

The immunization schedule protects against 14 potentially serious diseases before a child’s second birthday, as recommended ...

Hamilton families have one last chance to get their babies immunized against a common virus that can cause serious lung infections before a clinic at McMaster Children’s Hospital closes. The ...

This isn't just another routine winter — we’re facing a perfect storm of respiratory threats that are showing tremendous ...

Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF ...

Nirsevimab is a long-acting monoclonal antibody designed to provide passive immunity against RSV in infants and young children. The Advisory Committee on Immunization Practices (ACIP) recommends ...

Bimekizumab showed higher PASI100 response rates at weeks 4 and 16 compared to brodalumab, indicating superior efficacy. Discontinuation due to inefficacy was more frequent with brodalumab, though ...